Tilray Brands, Inc. (TLRY.TO)
CAD 0.62
(-6.06%)
CAD 0.62
(-6.06%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 410.32 Million USD | 3.38% |
| 2022 | 325.1 Million USD | -5.87% |
| 2021 | 345.37 Million USD | 80.12% |
| 2020 | 191.74 Million USD | 41.24% |
| 2019 | 135.75 Million USD | 31.88% |
| 2018 | 102.94 Million USD | 175.83% |
| 2017 | 37.31 Million USD | 231.0% |
| 2016 | 11.27 Million USD | 108.06% |
| 2015 | 5.41 Million USD | -9.82% |
| 2014 | 6 Million USD | 540.75% |
| 2013 | 937.88 Thousand USD | 1968.69% |
| 2012 | 45.33 Thousand USD | -53.98% |
| 2011 | 98.51 Thousand USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 89.3 Million USD | -9.49% |
| 2023 FY | 336.1 Million USD | 3.38% |
| 2023 Q4 | 93.03 Million USD | 12.4% |
| 2023 Q3 | 82.76 Million USD | 0.81% |
| 2023 Q2 | 82.1 Million USD | 4.97% |
| 2023 Q1 | 78.21 Million USD | -9.49% |
| 2022 Q4 | 86.41 Million USD | 12.97% |
| 2022 Q2 | 84.03 Million USD | 2.64% |
| 2022 Q3 | 76.49 Million USD | -8.97% |
| 2022 Q1 | 81.87 Million USD | -11.69% |
| 2022 FY | 325.1 Million USD | -5.87% |
| 2021 Q2 | 79.33 Million USD | -15.52% |
| 2021 Q1 | 93.9 Million USD | 49.22% |
| 2021 Q3 | 84.31 Million USD | 6.28% |
| 2021 FY | 345.37 Million USD | 80.12% |
| 2021 Q4 | 92.71 Million USD | 9.97% |
| 2020 Q2 | 46.3 Million USD | 17.64% |
| 2020 Q3 | 69.05 Million USD | 49.13% |
| 2020 FY | 191.74 Million USD | 41.24% |
| 2020 Q4 | 62.93 Million USD | -8.86% |
| 2020 Q1 | 39.36 Million USD | 7.55% |
| 2019 Q4 | 36.59 Million USD | 1.34% |
| 2019 Q1 | 30.44 Million USD | 5.07% |
| 2019 Q2 | 36.46 Million USD | 19.77% |
| 2019 Q3 | 36.11 Million USD | -0.97% |
| 2019 FY | 135.75 Million USD | 31.88% |
| 2018 Q1 | 17.9 Million USD | 7.89% |
| 2018 Q4 | 28.97 Million USD | -19.91% |
| 2018 FY | 102.94 Million USD | 175.83% |
| 2018 Q3 | 36.18 Million USD | 81.88% |
| 2018 Q2 | 19.89 Million USD | 11.13% |
| 2017 Q2 | 5.7 Million USD | 10.53% |
| 2017 FY | 37.31 Million USD | 231.0% |
| 2017 Q4 | 16.59 Million USD | 68.11% |
| 2017 Q3 | 9.87 Million USD | 72.86% |
| 2017 Q1 | 5.16 Million USD | 92.3% |
| 2016 Q1 | 2.28 Million USD | 29.73% |
| 2016 FY | 11.27 Million USD | 108.06% |
| 2016 Q3 | 3.56 Million USD | 31.72% |
| 2016 Q4 | 2.68 Million USD | -24.61% |
| 2016 Q2 | 2.7 Million USD | 18.27% |
| 2015 Q4 | 1.76 Million USD | 21.47% |
| 2015 Q3 | 1.45 Million USD | 8.78% |
| 2015 Q1 | 908.56 Thousand USD | -3.37% |
| 2015 FY | 5.41 Million USD | -9.82% |
| 2015 Q2 | 1.33 Million USD | 46.87% |
| 2014 Q1 | 8316.12 USD | -86.85% |
| 2014 Q4 | 940.24 Thousand USD | -65.72% |
| 2014 Q3 | 2.74 Million USD | 42213.03% |
| 2014 FY | 6 Million USD | 540.75% |
| 2014 Q2 | 6482.23 USD | -22.05% |
| 2013 Q1 | 7855.65 USD | 73.67% |
| 2013 Q4 | 63.26 Thousand USD | 33.93% |
| 2013 Q3 | 47.23 Thousand USD | 933.35% |
| 2013 Q2 | 4571.06 USD | -41.81% |
| 2013 FY | 937.88 Thousand USD | 1968.69% |
| 2012 Q2 | 20.45 Thousand USD | 49.82% |
| 2012 Q3 | 13.33 Thousand USD | -34.85% |
| 2012 Q4 | 4523.23 USD | -66.07% |
| 2012 Q1 | 13.65 Thousand USD | -24.11% |
| 2012 FY | 45.33 Thousand USD | -53.98% |
| 2011 Q2 | 3424.37 USD | 0.0% |
| 2011 Q4 | 17.99 Thousand USD | -72.63% |
| 2011 FY | 98.51 Thousand USD | 0.0% |
| 2011 Q3 | 65.73 Thousand USD | 1819.74% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Aurora Cannabis Inc. | 158.53 Million CAD | -158.817% |
| Avicanna Inc. | 14.59 Million CAD | -2712.05% |
| Avant Brands Inc. | 5.65 Million CAD | -7150.857% |
| Cardiol Therapeutics Inc. | 29.53 Million CAD | -1289.186% |
| Crescita Therapeutics Inc. | 12.32 Million CAD | -3230.568% |
| Knight Therapeutics Inc. | 155.54 Million CAD | -163.804% |
| MediPharm Labs Corp. | 23.08 Million CAD | -1677.611% |
| OrganiGram Holdings Inc. | 277.81 Million CAD | -47.699% |
| Canopy Growth Corporation | 308.61 Million CAD | -32.959% |
| Willow Biosciences Inc. | 7.55 Million CAD | -5331.904% |
| Auxly Cannabis Group Inc. | 40.28 Million CAD | -918.634% |